K-3505
/ Kallyope
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
November 29, 2024
A Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-3505 in Healthy Volunteers (PART II)
(ANZCTR)
- P1 | N=12 | Withdrawn | Sponsor: KALLYOPE, Inc. | Not yet recruiting ➔ Withdrawn
Trial withdrawal • CNS Disorders • Migraine • Pain
November 29, 2024
A Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-3505 in Healthy Volunteers (PART I).
(ANZCTR)
- P1 | N=28 | Withdrawn | Sponsor: KALLYOPE, Inc. | Not yet recruiting ➔ Withdrawn
Trial withdrawal • CNS Disorders • Migraine • Pain
August 23, 2024
A Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-3505 in Healthy Volunteers (PART II)
(ANZCTR)
- P1 | N=12 | Not yet recruiting | Sponsor: KALLYOPE, Inc.
New P1 trial • CNS Disorders • Migraine • Pain
1 to 3
Of
3
Go to page
1